OncoMatch/Clinical Trials/NCT04662294
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Is NCT04662294 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies CD70 CAR T-cells for acute myeloid leukemia.
Treatment: CD70 CAR T-cells — A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Biomarker criteria
Required: CD70 positive
CD70 AML
Required: CD70 positive
CD70+ NHL
Required: CD70 positive
CD70 multiple myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: car-t cell therapy
Lab requirements
Kidney function
creatinine ≤ 176.8 umol/l
Liver function
total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal
Cardiac function
echocardiogram shows left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04662294 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior car-t cell therapy disqualifies patients from enrollment.
Does this trial require CD70?
Yes, CD70 positive is a required biomarker for enrollment.
Does this trial require CD70?
Yes, CD70 positive is a required biomarker for enrollment.
Does this trial require CD70?
Yes, CD70 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify